Breakout Ventures’ Post

We build with visionary entrepreneurs who don't accept the status quo. The 10 years and $1B+ it takes to bring medicines from discovery to approval is unacceptable... and ready to be overhauled by computation.     At our 2024 Magnify Debate, we tackled the question: 𝐈𝐟 𝐌𝐋+𝐀𝐈 𝐡𝐚𝐯𝐞 𝐭𝐡𝐞 𝐩𝐨𝐭𝐞𝐧𝐭𝐢𝐚𝐥 𝐭𝐨 𝐢𝐦𝐩𝐚𝐜𝐭 𝐞𝐯𝐞𝐫𝐲 𝐬𝐭𝐞𝐩 𝐢𝐧 𝐭𝐡𝐞 𝐝𝐫𝐮𝐠 𝐝𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐩𝐫𝐨𝐜𝐞𝐬𝐬, 𝐰𝐡𝐞𝐫𝐞 𝐰𝐢𝐥𝐥 𝐭𝐡𝐞 𝐟𝐮𝐧𝐧𝐞𝐥 𝐦𝐞𝐚𝐧𝐢𝐧𝐠𝐟𝐮𝐥𝐥𝐲 𝐜𝐡𝐚𝐧𝐠𝐞 𝐬𝐡𝐚𝐩𝐞 𝐟𝐢𝐫𝐬𝐭?   Arguing for expanding the top of the funnel "Going Wide" David Younger of A-Alpha Bio and Karen Akinsanya of Schrödinger championed expanding the search space to design molecules even nature hasn't seen. Fighting for improving success at the bottom of the funnel "Going Narrow" Ron Alfa, MD, PhD of NOETIK and Etai Jacob of AstraZeneca explained how going deeper into underlying biology will improve translation to humans and deliver on the promises of precision medicine. So who won? Check the highlight video and let us know your vote. PS - Interested in attending next year's event? Sign up for our newsletter to be the first to know: https://lnkd.in/d3eRkTnG

Learn more about our portfolio of founders who dare to ask the big questions: https://www.breakout.vc/portfolio/

Susanna Harris, PhD

Helping Scientists Communicate | Biotech Venture

4d

Thank you to David Younger, Ron Alfa, MD, PhD, Karen Akinsanya, and Etai Jacob for taking the main stage this year!

Shivam K. Shodhan

Life Sciences Executive | Strategy, CorpDev, HR/People, BizOps Leadership

3d

An excellent event and debate, as always!

Like
Reply
Ron Alfa, MD, PhD

Co-Founder/CEO NOETIK.ai • Former Recursion (RXRX) • Stanford MD•PHD • Build the future

4d

Fantastic event, thank you for hosting!

See more comments

To view or add a comment, sign in

Explore topics